

U30066PCT
Charité - Universitätsmedizin Berlin

Abstract

5

The invention relates to the use of at least one proteasome inhibitor, preferably in the form of a threonine protease inhibitor, in the treatment of fibrotic diseases, especially fibrotic diseases of the cardiovascular system.

Notes to the translation:

On page 2, line 29, "duplex forming oligonucleotide" is in disagreement with claim 10 and should be corrected

5

Claims 7 to 10 have been corrected to recite the correct referral numbers